I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

62.4 million Indians were reported to have type 2 diabetes mellitus (T2DM) putting India on the forefront of diabetic epidemic across globe.\[[@ref1][@ref2]\] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.\[[@ref3]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref4]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref5]\] This short communication presents the results for patients enrolled from Gujarat, India.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A1chieve study: Mapping the Ibn Battuta trail

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 812 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients (61.82%) started on or switched to biphasic insulin aspart. Other groups were insulin detemir (*n* = 89), insulin aspart (*n* = 155), basal insulin plus insulin aspart (*n* = 45) and other insulin combinations (*n* = 21).

###### 

Overall demographic data

![](IJEM-17-521-g001)

After 24 weeks of treatment, overall hypoglycaemia reduced from 0.7 events/patient-year to 0.2 events/patient-year in insulin naïve group and from 1.8 events/patient-year to 0.3 events/patient-year in insulin user group. The hypoglycaemia incidence in insulin naive group at 24 weeks was lower than that observed in insulin users at baseline. SADRs including major hypoglycaemic events did not occur in any of the study patients. Body weight and blood pressure decreased from baseline, while overall lipid profile and quality of life improved at week 24 in the total cohort \[Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall safety data
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###### 

Insulin dose
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Mean HbA~1~c and FPG values improved from baseline to study end in the total cohort \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data
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Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 502 patients started on biphasic insulin aspart ± OGLD, of which 372 (74.1%) were insulin naïve and 130 (25.9%) were insulin users. After 24 weeks of treatment, hypoglycaemic events reduced for both insulin naive (from 0.9 events/patient-year to 0.3 events/patient-year) and insulin user (from 1.4 events/patient-year to 0.4 events/patient-year) groups. Body weight decreased and quality of life improved at the end of the study \[Table [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose

![](IJEM-17-521-g006)

Mean HbA~1~c and FPG values improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data
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Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 45 patients started on basal + insulin aspart ± OGLD, of which 33 (73.3%) were insulin naïve and 12 (26.7%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 0.4 events/patient-year to 0.0 events/patient-year in insulin naïve group and from 7.6 events/patient-year to 0.0 events/patient-year in insulin user group. A decrease in body weight was observed. Quality of life improved at 24 weeks \[Table [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose

![](IJEM-17-521-g009)

Mean HbA~1~c and FPG values improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data
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Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 89 patients started on insulin detemir ± OGLD, of which 66 (74.2%) were insulin naïve and 23 (25.8%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart hypoglycaemic events reduced from 0.8 events/patient-year to 0.0 events/patient-year in insulin naïve group and from 0.6 events/patient-year to 0.0 events/patient-year in insulin user group. A decrease in body weight was observed. Quality of life improved at 24 weeks \[Table [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data
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###### 

Insulin dose
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Mean HbA~1~c and FPG values improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data
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Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 155 patients started on insulin aspart ± OGLD, of which 122 (78.7%) were insulin naïve and 33 (21.3%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemic events reduced from 0.1 events/patient-year to 0.0 events/patient-year in insulin naïve group and from 1.6 events/patient-year to 0.0 events/patient-year in insulin user group. A decrease in body weight was observed. Quality of life improved at 24 weeks \[Table [14](#T14){ref-type="table"} and [15](#T15){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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Mean HbA~1~c and FPG values improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 16](#T16){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-521-g016)

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control and quality of life following 24 weeks of treatment with any of the insulin analogues (biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. A small weight reduction was noted for all the four regimens. SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Gujarat, India.
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